Abstract
Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 444-449 |
| Number of pages | 6 |
| Journal | Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program |
| Volume | 2012 |
| State | Published - 2012 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Childhood immune thrombocytopenia : role of rituximab, recombinant thrombopoietin, and other new therapeutics. / Journeycake, Janna M.
In: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, Vol. 2012, 2012, p. 444-449.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Childhood immune thrombocytopenia
T2 - role of rituximab, recombinant thrombopoietin, and other new therapeutics.
AU - Journeycake, Janna M.
PY - 2012
Y1 - 2012
N2 - Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.
AB - Childhood immune thrombocytopenia (ITP) is often considered a benign hematologic disorder. However, 30% of affected children will have a prolonged course and 5%-10% will develop chronic severe refractory disease. Until recently, the only proven therapeutic option for chronic severe ITP was splenectomy, but newer alternatives are now being studied. However, because immunosuppressive agents such as rituximab are not approved for use in ITP and the thrombopoietin receptor agonists are not yet approved in children, the decision to use alternatives to splenectomy needs to be considered carefully. This review describes the factors that should affect decisions to treat ITP at diagnosis and compares the options for the occasional child in whom ITP does not resolve within the first year.
UR - http://www.scopus.com/inward/record.url?scp=84879363483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879363483&partnerID=8YFLogxK
M3 - Article
C2 - 23233617
AN - SCOPUS:84879363483
VL - 2012
SP - 444
EP - 449
JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
SN - 1520-4391
ER -